STAT+: Pharmalittle: We’re reading about CVS and Humira biosimilars, Schumer’s broken insulin promise, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
Category: STAT+
STAT+: Intra-Cellular reports positive results in depression study aimed at expanding use of antispsychotic medicine
Intra-Cellular Therapies reported positive results Tuesday from a late-stage clinical trial seeking to expand the…
STAT+: Chuck Schumer’s broken promise on affordable insulin
WASHINGTON — In February 2022, Senate Majority Leader Chuck Schumer stood alongside constituents in Buffalo,…
STAT+: A new PIPE lawsuit challenges the fairness of sharing confidential, stock-moving information
The fairness of PIPEs, particularly the preferential sharing of confidential, stock-moving information, is now a…
STAT+: Grocers are pushing legislation they claim would enhance food safety. Advocates say it would gut FDA rules
WASHINGTON – In the last decade, Americans have been sickened by salmonella from cucumbers, listeria…
STAT+: Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing huge market share
The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment,…
.jpg)
STAT+: Cerebral to pay $7 million fine and limit health data use for ads under federal order
Telehealth company Cerebral will limit the consumer health data it uses for advertising purposes under…
STAT+: Pharmalittle: We’re reading about a J&J cough syrup, a Pfizer and Moderna patent suit, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition
Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome,…
STAT+: Can investing in infectious disease pay off? Vir Biotechnology’s tightrope walk shows it’s a struggle
Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch…
STAT+: Mass General Brigham is ready to move on without Dana-Farber, CEO says
CHICAGO — The split between Dana-Farber Cancer Institute and Mass General Brigham has been messy….
STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps
In response to controversy, a group of Colorado lawmakers is abandoning a bill that would…
STAT+: FTC cracks down on telehealth addiction service Monument for sharing health data
On Thursday, the Federal Trade Commission took action against alcohol addiction telehealth company Monument, affirming…
STAT+: The inside story of Enhertu’s pan-tumor approval
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions
The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the…
STAT+: When a cancer drug fails, oncologists often fly blind. A precision technique might light the way
It seemed as if Logan Jenner had the best possible chance for a cure. Diagnosed…
STAT+: Telehealth providers can drive antibiotic overuse — or choose to combat it
Ho Anh had just started working at Lemonaid Health when he was caught up in…
STAT+: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025
Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the…
STAT+: Drug shortages reached a record high as 2023 drew to a close
The number of ongoing and active drug shortages in the U.S. stood at 323 during…
STAT+: Regeneron accused by Justice Department of manipulating Medicare pricing
The U.S. Department of Justice filed a lawsuit accusing Regeneron Pharmaceuticals of manipulating Medicare pricing…
STAT+: Vertex to buy Alpine Immune Sciences for $4.9 billion
Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the…
STAT+: BIO’s top lobbyist exits, signaling reorganization
WASHINGTON — The biotech industry’s largest trade group has parted ways with its top lobbyist,…
.jpg)
STAT+: Pharmalittle: We’re reading about a 486% drug price hike, AstraZeneca CEO pay, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Did you say 486%? Why one company thinks such a price hike for its drug is justified
In an era when huge price hikes for prescription drugs are almost guaranteed to draw…
STAT+: Cancer vaccines gain momentum, after years of disappointing results
SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. But…
STAT+: Virginia governor vetoes plans to create a prescription drug affordability board
Virginia Gov. Glenn Youngkin vetoed a bill that would have created a new entity for…
STAT+: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost
In the latest gambit to lower the cost of a pricey medicine, three advocacy groups…
STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: MassMutual is rolling out free genetic testing for members, a dicey area for life insurers
One of the country’s biggest life insurers is venturing into genetic testing, an area that’s…
STAT+: Biotech startups post strongest financing numbers in two years
The numbers are in, and biotech startups recently closed out their best fundraising quarter in…
STAT+: Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells
The team behind Karuna Therapeutics, which was recently snapped up in a multibillion-dollar deal, on…
STAT+: Device made by company J&J is buying for $13 billion clears hurdle in independent study
A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave…
STAT+: New liquid biopsy screening test for pancreatic cancer shows promise in early data
For the vast majority of pancreatic cancer cases, the tumor grows undetected until it has…
STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on
File this under “Not a moment too soon.” After years of back-and-forth deliberations, the U.S….
STAT+: HCA reports almost $1 billion more in charity care to Medicare than to its shareholders, drawing more taxpayer money
The country’s biggest hospital chain, HCA Healthcare, told the Centers for Medicare and Medicaid Services…
STAT+: WHO scientists question Grail’s plan for evaluating its multi-cancer Galleri blood test
A new analysis published Sunday challenges the clinical trial endpoint the cancer screening firm Grail…
STAT+: About half of cancer drugs given accelerated approval don’t improve survival or quality of life
SAN DIEGO — For decades, the Food and Drug Administration’s accelerated approval pathway has helped…
STAT+: Cancer is rising among the young. Study suggests it’s because their cells are aging faster
SAN DIEGO — Cancer cases among younger people have been rising for years, a trend…
STAT+: In first big randomized trial, Abiomed’s heart pump reduced deaths in heart attack patients
A controversial heart pump from Abiomed reduced the number of deaths in severe heart attack…
STAT+: Alnylam’s twice-a-year drug lowered blood pressure when combined with common pills
ATLANTA — New trial results show that a drug candidate from Alnylam Pharmaceuticals can lead…
STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure
ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity,…
STAT+: Teladoc CEO Jason Gorevic to leave the company
In a decision that surprised Wall Street analysts, Teladoc Health announced that long-time CEO Jason…
STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Johnson & Johnson to buy Shockwave Medical for $13.1 billion
Johnson & Johnson on Friday announced it would acquire heart device firm Shockwave Medical for…
STAT+: Nuclear Regulatory Commission advisers beset by conflicts of interest, report finds
The oversight division of a U.S. government agency tasked with ensuring the safe use of…
STAT+: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar…
STAT+: Weed for weight loss, and more from Biotech Land
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…
STAT+: Matt & Adam’s Take: Amylyx did the right thing by withdrawing its ALS drug. That’s rare and worthy of praise
On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug, Relyvrio, after…